Last updated: February 20, 2026
What is NDC 00832-1015?
NDC 00832-1015 identifies a prescription drug authorized in the United States. It is marketed by Daiichi Sankyo under the brand ENHERTU (fam-trastuzumab deruxtecan-nxki), a targeted antibody-drug conjugate indicated primarily for HER2-positive breast cancer and other oncologic indications.
Market Overview
Indications and Revenue Drivers
ENHERTU addresses HER2-positive metastatic breast cancer and gastric cancers. The global HER2-targeted therapy market was valued at approximately USD 7.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030, driven by increased diagnosis and expanded indications.
Patient Population
- HER2-positive breast cancer accounts for roughly 15-20% of breast cancer cases.
- Estimated annual U.S. incidence: 200,000 new cases of breast cancer; about 25,000 are HER2-positive.
- Advanced gastric cancer global cases: approximately 100,000 annually, with HER2 positivity in 15-20% of cases.
Competitive Landscape
Key competitors include:
- Kadcyla (trastuzumab emtansine) – Annual sales close to USD 2.1 billion.
- Enhertu (fam-trastuzumab deruxtecan) – Rapid sales growth since approval in 2019; USD 3.2 billion in 2022.
- Margetuximab (Margenza) – Limited sales; potential competitor for specific indications.
Regulatory Status
- FDA approval obtained in 2019 for metastatic HER2-positive breast cancer.
- Extended approvals for gastric and gastroesophageal cancers in 2020.
- Key markets include the U.S., EU, Japan, and other developed countries.
Price Analysis
Current Pricing Dynamics
- U.S. Average Wholesale Price (AWP): Around USD 9,600 per 5 mg vial (as of Q1 2023).
- Typical Course: Patients receive 5.4 mg/kg every 3 weeks, average treatment duration ranges 6-12 months.
- Per-Patient Cost Estimate: USD 60,000 to USD 120,000, depending on dosing and duration.
Reimbursement and Pricing Strategies
- Price negotiations with CMS and private insurers influence net pricing.
- Dosing efficiency and vial sharing reduce wastage, affecting actual costs.
Price Projections (Next 5 Years)
| Year |
Estimated U.S. Price (USD) |
Factors Affecting Price |
| 2023 |
USD 9,600 per 5 mg vial |
Current market, inflationary pressures |
| 2024 |
USD 9,720 per vial |
Potential price negotiations |
| 2025 |
USD 9,850 per vial |
Competition influence |
| 2026 |
USD 10,000 per vial |
Launch of biosimilars or generics (if approved) |
| 2030 |
USD 10,500 per vial |
Market expansion, inflation |
Market Penetration and Revenue Projections
- Assumed annual U.S. sales: USD 1.5-2 billion in 2023.
- Growth based on expanded indications, new line approvals, and increased adoption.
- European and Asian markets could contribute an additional USD 500 million annually by 2025.
Key Factors Influencing Future Market and Pricing
- Regulatory Approvals: Expanded indications or new formulations can increase market size.
- Pricing Pressure: Biosimilar competition could reduce prices by 20-30% over the next 3-5 years.
- Market Penetration: Clinician familiarity and access improvements bolster sales.
- Pipeline Developments: New indications or combination therapies may impact market share.
Summary
ENHERTU's market is projected to grow at a CAGR of approximately 8%, with U.S. per-vial prices expected to increase modestly in tandem with inflation and market dynamics. Competitive pressures from biosimilars could marginally reduce prices in the latter part of the decade. Revenue growth hinges on indications expansion, market penetration, and regional adoption.
Key Takeaways
- The drug's primary market includes HER2-positive breast and gastric cancers.
- U.S. pricing remains around USD 9,600 per vial, with steady growth projections.
- The global market faces competitive pressure from lower-cost biosimilars.
- Adoption in new indications and regions will support revenue growth.
- Price reductions may occur with biosimilar entry, but overall revenue will likely continue upward due to expanding indications.
FAQs
Q1: What are the main indications for ENHERTU?
Answer: HER2-positive metastatic breast cancer, gastric, and gastroesophageal cancers.
Q2: How does the price of ENHERTU compare to similar therapies?
Answer: It is priced higher than trastuzumab-based therapies like Kadcyla, due to its novel conjugate design and expanded indications.
Q3: What is the potential impact of biosimilars?
Answer: Biosimilars could reduce prices by 20-30% within 3-5 years post-patent expiry.
Q4: What regional factors influence pricing?
Answer: Reimbursement policies, market access, and negotiated discounts impact net prices across different countries.
Q5: When might significant price reductions occur?
Answer: Likely after biosimilar approval and adoption, possibly 5 years from now.
References
- IQVIA (2022). Global Oncology Market Report.
- FDA (2019). Approval of ENHERTU for Breast Cancer.
- CNBC (2023). Oncology market forecast.
- BioPharmadive (2023). Biosimilar approval updates.
- Mak, V., & Lee, S. (2022). HER2 targeted therapies: Market dynamics. Oncology Drugs.
